Accelerate Diagnostics (NASDAQ: AXDX) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare Accelerate Diagnostics to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.
This is a breakdown of current recommendations for Accelerate Diagnostics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Accelerate Diagnostics Competitors||416||2179||3383||122||2.53|
Accelerate Diagnostics currently has a consensus target price of $33.00, indicating a potential upside of 39.83%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 22.06%. Given Accelerate Diagnostics’ stronger consensus rating and higher probable upside, analysts clearly believe Accelerate Diagnostics is more favorable than its rivals.
Risk and Volatility
Accelerate Diagnostics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics’ rivals have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.
Valuation & Earnings
This table compares Accelerate Diagnostics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Accelerate Diagnostics||$1.29 million||-$61.92 million||-19.19|
|Accelerate Diagnostics Competitors||$2.01 billion||$429.46 million||-58.52|
Accelerate Diagnostics’ rivals have higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Accelerate Diagnostics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Accelerate Diagnostics Competitors||-330.24%||-33.51%||-12.50%|
Insider & Institutional Ownership
44.4% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 51.4% of Accelerate Diagnostics shares are held by insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Accelerate Diagnostics rivals beat Accelerate Diagnostics on 7 of the 12 factors compared.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.